Expasy logo

UniProtKB/Swiss-Prot variant pages

Due to maintenance work, this service will be unavailable on Monday between 06:00 until 06:30 CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot Q9HC29: Variant p.Thr605Asn

Nucleotide-binding oligomerization domain-containing protein 2
Gene: NOD2
Variant information Variant position: help 605 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Threonine (T) to Asparagine (N) at position 605 (T605N, p.Thr605Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and polar. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In BLAUS; hyperactive. Any additional useful information about the variant.

Sequence information Variant position: help 605 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1040 The length of the canonical sequence.
Location on the sequence: help LVRAKGVVPGSTAPLEFLHI T FQCFFAAFYLALSADVPPAL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.





Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
Chain 1 – 1040 Nucleotide-binding oligomerization domain-containing protein 2
Domain 293 – 618 NACHT
Binding site 603 – 603
Alternative sequence 225 – 1040 Missing. In isoform 3.
Mutagenesis 600 – 600 E -> A. Increased NF-kappa-B activation in response to muramyl dipeptide stimulation.
Mutagenesis 603 – 603 H -> A. Does not affect NF-kappa-B activation in response to muramyl dipeptide stimulation.

Literature citations
Blau syndrome polymorphisms in NOD2 identify nucleotide hydrolysis and helical domain 1 as signalling regulators.
Parkhouse R.; Boyle J.P.; Monie T.P.;
FEBS Lett. 588:3382-3389(2014)
Cited for: SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS BLAUS GLN-334; TRP-334; GLY-383; LYS-383; PHE-469; ASP-481; LEU-490; TYR-495; LEU-496; THR-513; CYS-587; ASN-605; PRO-605 AND LYS-670; CHARACTERIZATION OF VARIANTS AND CYS-471; A novel mutation in the NOD2 gene associated with Blau syndrome: a Norwegian family with four affected members.
Milman N.; Ursin K.; Rodevand E.; Nielsen F.C.; Hansen T.V.;
Scand. J. Rheumatol. 38:190-197(2009)
Cited for: VARIANT BLAUS ASN-605;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.